BASEL, SwitzerlandThe European Commission (EC) has granted approval for Novartis' Exjade (deferasirox) to treat patients with transfusional iron overload in all 25 member states of the European Union (EU). Exjade, available in the United States, is an oral iron chelator that provides continuous chelation coverage with a single daily dose.

Articles

Palliative and Supportive Care

Oncology NEWS International Vol 15 No 9

The European Commission (EC) has granted approval for Novartis' Exjade (deferasirox) to treat patients with transfusional iron overload in all 25 member states of the European Union (EU). Exjade, available in the United States, is an oral iron chelator that provides continuous chelation coverage with a single daily dose.

Exjade Gains Approval in EU